Fillerina is a product manufactured and marketed by a Swiss Registered company called LABO Cosprophar. The same company manufactures and markets Crescina, a hair growth product like Evolis and another face treatment product called Lato Transdemic. The company has a presence in over 32 countries in Europe, USA, Middle East and North Africa. The markets are aggressively marketed via its Italian branch.
If a customer has bought Fillerina and is pretty satisfied and now wants a hair growth product, do you think he/she will go for Evolis or Crescina? The chances are he/she will go for the product from the company he/she has confidence with and that will be Crescina.
By distributing Fillerina, are we not helping our competitor take away our market share of Evolis? Just a thought.
- Forums
- ASX - By Stock
- AN1
- Ann: Preliminary Final Report
Ann: Preliminary Final Report, page-64
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online